PE20180023A1 - METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT - Google Patents
METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENTInfo
- Publication number
- PE20180023A1 PE20180023A1 PE2016000848A PE2016000848A PE20180023A1 PE 20180023 A1 PE20180023 A1 PE 20180023A1 PE 2016000848 A PE2016000848 A PE 2016000848A PE 2016000848 A PE2016000848 A PE 2016000848A PE 20180023 A1 PE20180023 A1 PE 20180023A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- hsdd
- trazodone
- bupropion
- women
- Prior art date
Links
- 206010024419 Libido decreased Diseases 0.000 title abstract 5
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 title abstract 5
- 208000017020 hypoactive sexual desire disease Diseases 0.000 title abstract 5
- 229960001058 bupropion Drugs 0.000 title abstract 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960003991 trazodone Drugs 0.000 title abstract 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a un metodo de tratamiento de una mujer con trastorno del deseo sexual hipoactivo (HSDD) que comprende: a) administracion diaria de un primer farmaco tal como bupropion que tiene una concentracion de dosis de 150 mg; b) administracion diaria de un segundo farmaco tal como trazodona que tiene una concentracion de dosis de 75 mg; y c) dicha administracion del primer y segundo farmaco se encuentra de acuerdo con un regimen de tratamiento prescrito para el tratamiento la mujer para HSDDIt relates to a method of treating a woman with hypoactive sexual desire disorder (HSDD) comprising: a) daily administration of a first drug such as bupropion having a dose concentration of 150 mg; b) daily administration of a second drug such as trazodone having a dose concentration of 75 mg; and c) said administration of the first and second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351904P | 2016-06-17 | 2016-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180023A1 true PE20180023A1 (en) | 2018-01-09 |
Family
ID=57758862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000848A PE20180023A1 (en) | 2016-06-17 | 2016-06-20 | METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR20170142797A (en) |
AR (2) | AR105047A1 (en) |
AU (1) | AU2016204151A1 (en) |
CA (1) | CA2933921A1 (en) |
CL (1) | CL2016001597A1 (en) |
MX (1) | MX2016008272A (en) |
PE (1) | PE20180023A1 (en) |
UY (1) | UY36742A (en) |
WO (1) | WO2017218018A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5897864A (en) * | 1996-05-23 | 1999-04-27 | Cohen; Alan J. | Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
KR20070014184A (en) * | 2004-04-22 | 2007-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | New pharmaceutical compositions for the treatment of sexual disorders ii |
EP1998773A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | New therapeutic combinations for the treatment of depression |
CA2881388A1 (en) * | 2012-08-06 | 2014-02-13 | S1 Pharmaceuticals, Inc. | Treatment regimens |
-
2016
- 2016-06-20 CA CA2933921A patent/CA2933921A1/en not_active Abandoned
- 2016-06-20 PE PE2016000848A patent/PE20180023A1/en unknown
- 2016-06-20 AU AU2016204151A patent/AU2016204151A1/en not_active Abandoned
- 2016-06-20 UY UY0001036742A patent/UY36742A/en not_active Application Discontinuation
- 2016-06-20 MX MX2016008272A patent/MX2016008272A/en unknown
- 2016-06-20 WO PCT/US2016/038386 patent/WO2017218018A1/en active Application Filing
- 2016-06-20 KR KR1020160076915A patent/KR20170142797A/en not_active Application Discontinuation
- 2016-06-20 CL CL2016001597A patent/CL2016001597A1/en unknown
- 2016-06-21 AR ARP160101828A patent/AR105047A1/en unknown
- 2016-06-21 AR ARP160101856A patent/AR105087A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR105047A1 (en) | 2017-08-30 |
CL2016001597A1 (en) | 2017-10-06 |
KR20170142797A (en) | 2017-12-28 |
AU2016204151A1 (en) | 2018-01-18 |
UY36742A (en) | 2016-12-30 |
MX2016008272A (en) | 2017-12-18 |
AR105087A1 (en) | 2017-09-06 |
CA2933921A1 (en) | 2017-12-17 |
WO2017218018A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000706A1 (en) | Derivatives of pyrazolopyrimidine as btk inhibitors for the treatment of cancer. | |
CO2017011536A2 (en) | Compositions comprising a combination of a programmed anti-death antibody 1 (pd-1) and another antibody | |
CL2017002996A1 (en) | Tetra-substituted alkene compounds and their use | |
CO2017001493A2 (en) | Kits comprising tigit inhibitors and anticancer agents | |
ECSP18024971A (en) | ADJUNCTIVE THERAPY WITH 25-HYDROXY VITAMIN D AND ITEMS OF THE SAME | |
GT201700167A (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER. | |
PE20142363A1 (en) | USES AND MANUFACTURING ARTICLE INCLUDING HER2 PERTUZUMAB DIMERIZATION INHIBITOR | |
CL2016002794A1 (en) | Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent | |
AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
AR098832A1 (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
MX2020004513A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
PE20180023A1 (en) | METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT | |
CL2017000636A1 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
MX2018002681A (en) | AGENT FOR ENHANCING IMMUNITY TO CANCER BY USING Allergin-1 ANTAGONIST. | |
EA202091743A1 (en) | DENDRITIC CELL VACCINATION PARALLEL WITH CHEMOTHERAPY | |
EA201891008A3 (en) | TREATMENT OF SYMPTOMS ASSOCIATED WITH ANDROGEN-DEPRIVATION THERAPY | |
CL2014003326A1 (en) | Injectable antioxidant formulation for intravenous use of sodium ascorbate - in high doses, and n-acetylcysteine as oxidizing agents, and deferoxamine as iron chelating agents, plus pharmaceutical excipients; method for administration and use in preventing repertfusion damage in patients with acute myocardial infection, undergoing primary cardiac angioplasty; and kit that contains it. | |
CL2018003184A1 (en) | An immunogenic composition for the treatment of cancer and methods for preparing it | |
AR097590A1 (en) | METHODS TO TREAT THE FRAGILE X SYNDROME AND RELATED DISORDERS | |
AR092169A1 (en) | PHARMACEUTICAL SYNERGIC COMPOSITION ADAPTED TO BE ADMINISTRABLE ORALALLY AS AN ANTIPARASITARY AND PROCESSES TO PREPARE IT | |
BR112018002433A2 (en) | pharmaceutical composition for migraine treatment | |
PE20170201A1 (en) | PHARMACEUTICAL DOSAGE FORMS | |
AR116417A1 (en) | COMBINATIONS OF TGFb INHIBITORS AND CDK INHIBITORS FOR CANCER TREATMENTS | |
UA105323U (en) | Method for treating mixed nematode-cestode invasion in chickens | |
UA99662U (en) | METHOD OF TREATMENT OF PREGNANCY OF PREGNANCY IN WOMEN WITH METABOLIC SYNDROME |